New agreement to open the door to next generation cell therapies

cnbplogosquare124 November 2015:

A new collaboration agreement has been announced today by Macquarie University and clinical-stage regenerative medicine company Regeneus Ltd, to commercialise a breakthrough cell selection technology that for the first time allows high potency secreting stem cells to be identified and selected for the manufacture of next generation cell therapies.

The technology was developed in a research group led by Professor Ewa Goldys and Dr Guozhen Liu at the Australian Research Council’s Centre of Excellence for Nanoscale BioPhotonics (CNBP) at Macquarie, and uses innovative cell labelling technologies to identify and select cells based on the molecules that they are secreting rather than their surface characteristics used currently.

Read more here: